Wize Pharma (Israel) Buy Hold or Sell Recommendation

    WIZP -- Israel Stock  

    ILS 213.00  10.20  5.03%

    Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding Wize Pharma is 'Not Rated'. Macroaxis provides Wize Pharma buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding WIZP positions. The advice algorithm takes into account all of Wize Pharma available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from WIZP buy-and-hold prospective. See also Your Current Watchlist.

    Time Horizon

    Risk Tolerance

    Execute Advice
    Sell Wize PharmaBuy Wize Pharma
    Not Rated
    For the selected time horizon Wize Pharma has a risk adjusted performance of 0.0, jensen alpha of 0.0, total risk alpha of 0.0, sortino ratio of 0.0 and treynor ratio of 0.0
    Macroaxis provides buy or sell recommendation on Wize Pharma to complement and cross-verify current analyst consensus on Wize Pharma. Our buy or sell advice engine determines the company potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. Use Wize Pharma Price to Book, Net Income and the relationship between Shares Outstanding and EBITDA to make sure your buy or sell decision on Wize Pharma is adequate.

    Wize Pharma Alerts

    Trading Alerts and Improvement Suggestions

    Wize Pharma is not yet fully synchronised with the market data
    Wize Pharma appears to be very risky and stock price may revert if volatility continues
    Wize Pharma has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
    The company has accumulated 707 K in total debt with debt to equity ratio (D/E) of 217.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Wize Pharma has Current Ratio of 0.23 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
    This company reported revenue of . Net Loss for the year was (1.91 M).
    WIZE PHARMA has accumulated about 275 K in cash with (1.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
    See also Your Current Watchlist. Please also try Price Transformation module to use price transformation models to analyze depth of different equity instruments across global markets.
    Search macroaxis.com